BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee BH, Kim N, Hwang TJ, Lee SH, Park YS, Hwang JH, Kim JW, Jeong SH, Lee DH, Jung HC. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter. 2010;15:38-45. [PMID: 20302588 DOI: 10.1111/j.1523-5378.2009.00735.x] [Cited by in Crossref: 85] [Cited by in F6Publishing: 81] [Article Influence: 7.1] [Reference Citation Analysis]
Number Citing Articles
1 Yoon K, Kim N, Lee JW, Yoon H, Shin CM, Park YS, Lee DH. Annual eradication rate of bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: A 15-year prospective study at a tertiary hospital in Korea. Helicobacter. 2020;25:e12685. [PMID: 32141173 DOI: 10.1111/hel.12685] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Rodríguez de Santiago E, Martín de Argila de Prados C, Marcos Prieto HM, Jorge Turrión MÃ, Barreiro Alonso E, Flores de Miguel A, de la Coba Ortiz C, Rodríguez Escaja C, Pérez Álvarez G, Ferre Aracil C, Aguilera Castro L, García García de Paredes A, Rodríguez Pérez A, Albillos Martínez A. Limited effectiveness with a 10-day bismuth-containing quadruple therapy (Pylera ® ) in third-line recue treatment for Helicobacter pylori infection. A real-life multicenter study. Helicobacter 2017;22:e12423. [DOI: 10.1111/hel.12423] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
3 Huh KY, Chung H, Kim YK, Lee S, Bhatia S, Takanami Y, Nakaya R, Yu KS. Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication. Br J Clin Pharmacol 2021. [PMID: 34080718 DOI: 10.1111/bcp.14934] [Reference Citation Analysis]
4 Yoon JH, Baik GH, Kim YS, Suk KT, Shin WG, Kim KH, Kim KO, Park CH, Baik IH, Jang HJ. Comparison of the Eradication Rate between 1- and 2-Week Bismuth-Containing Quadruple Rescue Therapies for Helicobacter pylori Eradication. Gut Liver. 2012;6:434-439. [PMID: 23170146 DOI: 10.5009/gnl.2012.6.4.434] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
5 Kim SG, Jung HK, Lee HL, Jang JY, Lee H, Kim CG, Shin WG, Shin ES, Lee YC; Korean College of Helicobacter and Upper Gastrointestinal Research. [Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition]. Korean J Gastroenterol. 2013;62:3-26. [PMID: 23954956 DOI: 10.4166/kjg.2013.62.1.3] [Cited by in Crossref: 113] [Cited by in F6Publishing: 75] [Article Influence: 14.1] [Reference Citation Analysis]
6 Nyssen OP, Perez-Aisa A, Rodrigo L, Castro M, Mata Romero P, Ortuño J, Barrio J, Huguet JM, Modollel I, Alcaide N, Lucendo A, Calvet X, Perona M, Gomez B, Gomez Rodriguez BJ, Varela P, Jimenez-Moreno M, Dominguez-Cajal M, Pozzati L, Burgos D, Bujanda L, Hinojosa J, Molina-Infante J, Di Maira T, Ferrer L, Fernández-Salazar L, Figuerola A, Tito L, de la Coba C, Gomez-Camarero J, Fernandez N, Caldas M, Garre A, Resina E, Puig I, O'Morain C, Megraud F, Gisbert JP. Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg). Helicobacter 2020;25:e12722. [PMID: 32656898 DOI: 10.1111/hel.12722] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Burgos‐santamaría D, Mcnicholl AG, Gisbert JP. Empirical Helicobacter pylori rescue therapy: an 18‐year single‐centre study of 1200 patients. GastroHep 2019;1:311-24. [DOI: 10.1002/ygh2.372] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 2.7] [Reference Citation Analysis]
8 Gisbert JP, Perez-Aisa A, Rodrigo L, Molina-Infante J, Modolell I, Bermejo F, Castro-Fernández M, Antón R, Sacristán B, Cosme A. Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection. Dig Dis Sci. 2014;59:383-389. [PMID: 24126798 DOI: 10.1007/s10620-013-2900-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
9 Kim YK, Kim JS, Kim B. Recent Trends of Helicobacter pylori Eradication Therapy in Korea. Korean J Helicobacter Up Gastrointest Res 2012;12:219. [DOI: 10.7704/kjhugr.2012.12.4.219] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
10 Lee JY, Kim N, Park KS, Kim HJ, Park SM, Baik GH, Shim KN, Oh JH, Choi SC, Kim SE, Kim WH, Park SY, Kim GH, Lee BE, Jo Y, Hong SJ. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial. BMC Gastroenterol. 2016;16:79. [PMID: 27460100 DOI: 10.1186/s12876-016-0490-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
11 Lee JW, Kim N, Kim JM, Nam RH, Kim JY, Lee JY, Lee DH, Jung HC. A comparison between 15-day sequential, 10-day sequential and proton pump inhibitor-based triple therapy for Helicobacter pylori infection in Korea. Scand J Gastroenterol. 2014;49:917-924. [PMID: 24988873 DOI: 10.3109/00365521.2014.896409] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
12 Marin AC, McNicholl AG, Gisbert JP. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). Expert Opin Pharmacother. 2013;14:843-861. [PMID: 23537368 DOI: 10.1517/14656566.2013.782286] [Cited by in Crossref: 55] [Cited by in F6Publishing: 42] [Article Influence: 6.1] [Reference Citation Analysis]
13 Kim JY, Kim NY, Kim SJ, Baik GH, Kim GH, Kim JM, Nam RH, Kim HB, Lee DH, Jung HC, Song IS. [Regional difference of antibiotic resistance of helicobacter pylori strains in Korea]. Korean J Gastroenterol 2011;57:221-9. [PMID: 21519175 DOI: 10.4166/kjg.2011.57.4.221] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
14 Chung JW, Lee GH, Jeong JY, Lee SM, Jung JH, Choi KD, Song HJ, Jung HY, Kim JH. Resistance of Helicobacter pylori strains to antibiotics in Korea with a focus on fluoroquinolone resistance. J Gastroenterol Hepatol. 2012;27:493-497. [PMID: 21793912 DOI: 10.1111/j.1440-1746.2011.06874.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
15 Kim JY, Lee SY, Kim H, Kim JH, Sung IK, Park HS. Efficacy of Seven-Day Potassium-Competitive Acid Blocker-Based First-Line Helicobacter Pylori Eradication Therapy Administered with Bismuth. Yonsei Med J 2021;62:708-16. [PMID: 34296548 DOI: 10.3349/ymj.2021.62.8.708] [Reference Citation Analysis]
16 Sung JK. Diagnosis and Treatment of <i>Helicobacter Pylori</i> Infection. Korean J Med 2015;89:149-56. [DOI: 10.3904/kjm.2015.89.2.149] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
17 Lin TF, Hsu PI. Second-line rescue treatment of Helicobacter pylori infection: Where are we now? World J Gastroenterol 2018; 24(40): 4548-4553 [PMID: 30386104 DOI: 10.3748/wjg.v24.i40.4548] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
18 Park JY, Kim JG. [New Helicobacter pylori Eradication Therapies]. Korean J Gastroenterol 2018;72:237-44. [PMID: 30642139 DOI: 10.4166/kjg.2018.72.5.237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Rispo A, Capone P, Castiglione F, Pasquale L, Rea M, Caporaso N. Fluoroquinolone-based protocols for eradication of Helicobacter pyloriWorld J Gastroenterol 2014; 20(27): 8947-8956 [PMID: 25083067 DOI: 10.3748/wjg.v20.i27.8947] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
20 Lee JW, Kim N, Nam RH, Park JH, Kim JM, Jung HC, Song IS. Mutations of Helicobacter pylori associated with fluoroquinolone resistance in Korea. Helicobacter. 2011;16:301-310. [PMID: 21762270 DOI: 10.1111/j.1523-5378.2011.00840.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
21 Chang YW, Shin GY, Kim JW, Moon JC, Chang EJ, Oh CH, Jang JY. Cost-Effectiveness of Empirical Bismuth-Based Quadruple Therapy and Tailored Therapy After Clarithromycin Resistance Tests for Helicobacter pylori Eradication. Dig Dis Sci. 2021;. [PMID: 33755825 DOI: 10.1007/s10620-021-06938-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
22 Kim YI, Lee JY, Kim CG, Park B, Park JY, Choi IJ. Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial. BMC Gastroenterol 2021;21:95. [PMID: 33653284 DOI: 10.1186/s12876-021-01680-1] [Reference Citation Analysis]
23 Jung HK, Kang SJ, Lee YC, Yang HJ, Park SY, Shin CM, Kim SE, Lim HC, Kim JH, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M; Korean College of Helicobacter and Upper Gastrointesinal Research. Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020. Korean J Intern Med 2021;36:807-38. [PMID: 34092054 DOI: 10.3904/kjim.2020.701] [Reference Citation Analysis]
24 Kwon S, Lee DH, Kang JB, Kim N, Park YS, Shin CM, Yoon H, Choi YJ. [The Efficacy of Bismuth-containing Quadruple Therapy after Moxifloxacin-based Sequential Therapy Failure in Helicobacter pylori Eradication]. Korean J Gastroenterol 2018;71:196-203. [PMID: 29684968 DOI: 10.4166/kjg.2018.71.4.196] [Reference Citation Analysis]
25 Kim SG, Jung HK, Lee HL, Jang JY, Lee H, Kim CG, Shin WG, Shin ES, Lee YC; Korean College of Helicobacter and Upper Gastrointestinal Research. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. J Gastroenterol Hepatol. 2014;29:1371-1386. [PMID: 24758240 DOI: 10.1111/jgh.12607] [Cited by in Crossref: 123] [Cited by in F6Publishing: 90] [Article Influence: 17.6] [Reference Citation Analysis]
26 Gisbert JP, McNicholl AG. Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies. Helicobacter. 2017;22. [PMID: 28464347 DOI: 10.1111/hel.12392] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 7.4] [Reference Citation Analysis]
27 Kwon YH, Kim N, Lee JY, Choi YJ, Yoon K, Hwang JJ, Lee HJ, Lee A, Jeong YS, Oh S. The Diagnostic Validity of Citric Acid-Free, High Dose (13)C-Urea Breath Test After Helicobacter pylori Eradication in Korea. Helicobacter. 2015;20:159-168. [PMID: 25640474 DOI: 10.1111/hel.12189] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
28 Lee JW, Kim N, Nam RH, Lee SM, Soo In C, Kim JM, Lee DH. Risk factors of rescue bismuth quadruple therapy failure for Helicobacter pylori eradication. Journal of Gastroenterology and Hepatology 2019;34:666-72. [DOI: 10.1111/jgh.14625] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
29 Gisbert JP. Rescue Therapy for Helicobacter pylori Infection 2012. Gastroenterol Res Pract. 2012;2012:974594. [PMID: 22536225 DOI: 10.1155/2012/974594] [Cited by in Crossref: 19] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
30 Lee SW, Kim HJ, Kim JG. Treatment of Helicobacter pylori Infection in Korea: A Systematic Review and Meta-analysis. J Korean Med Sci. 2015;30:1001-1009. [PMID: 26240475 DOI: 10.3346/jkms.2015.30.8.1001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
31 Salazar CO, Cardenas VM, Reddy RK, Dominguez DC, Snyder LK, Graham DY. Greater than 95% success with 14-day bismuth quadruple anti- Helicobacter pylori therapy: a pilot study in US Hispanics. Helicobacter. 2012;17:382-390. [PMID: 22967122 DOI: 10.1111/j.1523-5378.2012.00962.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
32 Choi JM, Kim SG. Diagnosis and Treatment of <i>Helicobacter Pylori</i> Infection: Korean and Overseas Guidelines. Korean J Med 2015;89:157-68. [DOI: 10.3904/kjm.2015.89.2.157] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
33 Lee BH, Kim N. Quadruple or triple therapy to eradicate H pylori. The Lancet 2011;377:877-8. [DOI: 10.1016/s0140-6736(11)60168-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
34 Gisbert JP. Tratamientos de rescate ante el fracaso erradicador de Helicobacter pylori. Gastroenterología y Hepatología 2011;34:89-99. [DOI: 10.1016/j.gastrohep.2010.10.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
35 O’Connor A, Gisbert JP, McNamara D, O’Morain C. Treatment of Helicobacter pylori infection 2010. Helicobacter. 2010;15 Suppl 1:46-52. [PMID: 21054653 DOI: 10.1111/j.1523-5378.2010.00774.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
36 Mahachai V, Vilaichone RK, Pittayanon R, Rojborwonwitaya J, Leelakusolvong S, Maneerattanaporn M, Chotivitayatarakorn P, Treeprasertsuk S, Kositchaiwat C, Pisespongsa P, Mairiang P, Rani A, Leow A, Mya SM, Lee YC, Vannarath S, Rasachak B, Chakravuth O, Aung MM, Ang TL, Sollano JD, Trong Quach D, Sansak I, Wiwattanachang O, Harnsomburana P, Syam AF, Yamaoka Y, Fock KM, Goh KL, Sugano K, Graham D. Helicobacter pylori management in ASEAN: The Bangkok consensus report. J Gastroenterol Hepatol. 2018;33:37-56. [PMID: 28762251 DOI: 10.1111/jgh.13911] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 12.8] [Reference Citation Analysis]
37 Kim TH, Park JM, Cheung DY, Oh JH. Comparison of 7- and 14-Day Eradication Therapy for Helicobacter pylori with First- and Second-Line Regimen: Randomized Clinical Trial. J Korean Med Sci 2020;35:e33. [PMID: 32030921 DOI: 10.3346/jkms.2020.35.e33] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
38 Jung HK, Kang SJ, Lee YC, Yang HJ, Park SY, Shin CM, Kim SE, Lim HC, Kim JH, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M;  Korean College of Helicobacter and Upper Gastrointestinal Research. Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea 2020. Gut Liver. 2021;15:168-195. [PMID: 33468712 DOI: 10.5009/gnl20288] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
39 Lee SY. Current progress toward eradicating Helicobacter pylori in East Asian countries: Differences in the 2013 revised guidelines between China, Japan, and South Korea. World J Gastroenterol 2014; 20(6): 1493-1502 [PMID: 24587624 DOI: 10.3748/wjg.v20.i6.1493] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
40 Shaikh T, Fallone CA. Effectiveness of Second through Sixth Line Salvage Helicobacter pylori Treatment: Bismuth Quadruple Therapy is Almost Always a Reasonable Choice. Can J Gastroenterol Hepatol 2016;2016:7321574. [PMID: 27446864 DOI: 10.1155/2016/7321574] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
41 Kwon YH, Kim N, Lee JY, Choi YJ, Yoon K, Nam RH, Suh JH, Lee JW, Lee DH. Comparison of the efficacy of culture-based tailored therapy for Helicobacter pylori eradication with that of the traditional second-line rescue therapy in Korean patients: a prospective single tertiary center study. Scand J Gastroenterol. 2016;51:270-276. [PMID: 26452405 DOI: 10.3109/00365521.2015.1095352] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
42 Miehlke S, Frederking D, Günther T, Glocker E, Eisele B, Andresen V, Schröder S, Morgner A. Efficacy of three-in-one capsule bismuth quadruple therapy for Helicobacter pylori eradication in clinical practice in a multinational patient population. Helicobacter 2017;22:e12429. [DOI: 10.1111/hel.12429] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
43 Miftahussurur M, Yamaoka Y. Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective. Molecules. 2015;20:6068-6092. [PMID: 25856059 DOI: 10.3390/molecules20046068] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
44 Chung JW, Lee JH, Jung HY, Yun SC, Oh TH, Choi KD, Song HJ, Lee GH, Kim JH. Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy. Helicobacter. 2011;16:289-294. [PMID: 21762268 DOI: 10.1111/j.1523-5378.2011.00844.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
45 Shin K, Cho MJ, Oh JH, Lim CH. Second-Line Bismuth-Containing Quadruple Therapy for Helicobacterpylori Infection: A 12-Year Study of Annual Eradication Rates. J Clin Med 2021;10:3273. [PMID: 34362057 DOI: 10.3390/jcm10153273] [Reference Citation Analysis]
46 Kim SE, Kim N, Park SM, Kim WH, Baik GH, Jo Y, Park KS, Lee JY, Shim K, Kim GH, Lee BE, Hong SJ, Park S, Choi SC, Oh JH, Kim HJ. Female Gender is a Poor Predictive Factor of Functional Dyspepsia Resolution after Helicobacter pylori Eradication: A Prospective, Multi-center Korean Trial. Korean J Gastroenterol 2018;72:286. [DOI: 10.4166/kjg.2018.72.6.286] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
47 Lee JW, Kim N, Kim JM, Nam RH, Chang H, Kim JY, Shin CM, Park YS, Lee DH, Jung HC. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter. 2013;18:206-214. [PMID: 23241101 DOI: 10.1111/hel.12031] [Cited by in Crossref: 172] [Cited by in F6Publishing: 145] [Article Influence: 17.2] [Reference Citation Analysis]
48 Cortés P, Nelson AD, Bi Y, Stancampiano FF, Murray LP, Pujalte GGA, Gomez V, Harris DM. Treatment Approach of Refractory Helicobacter pylori Infection: A Comprehensive Review. J Prim Care Community Health 2021;12:21501327211014087. [PMID: 33949229 DOI: 10.1177/21501327211014087] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Sierra F, Forero JD, Rey M. [Ideal treatment for Helicobacter pylori: a systematic review]. Rev Gastroenterol Mex 2014;79:28-49. [PMID: 24365458 DOI: 10.1016/j.rgmx.2013.03.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
50 Kim SE, Park MI, Park SJ, Moon W, Kim JH, Jung K, Kim HK, Lee YD. Second-line bismuth-containing quadruple therapy for Helicobacter pylori eradication and impact of diabetes. World J Gastroenterol 2017; 23(6): 1059-1066 [PMID: 28246480 DOI: 10.3748/wjg.v23.i6.1059] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
51 Delchier JC, Malfertheiner P, Thieroff-Ekerdt R. Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther. 2014;40:171-177. [PMID: 24863854 DOI: 10.1111/apt.12808] [Cited by in Crossref: 59] [Cited by in F6Publishing: 50] [Article Influence: 7.4] [Reference Citation Analysis]
52 Lee SM, Kim N, Kwon YH, Nam RH, Kim JM, Park JY, Lee YS, Lee DH. rdxA, frxA, and efflux pump in metronidazole-resistant Helicobacter pylori: Their relation to clinical outcomes. J Gastroenterol Hepatol 2018;33:681-8. [PMID: 28748532 DOI: 10.1111/jgh.13906] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
53 Kwon YH, Kim N, Lee JY, Choi YJ, Yoon K, Yoon H, Shin CM, Park YS, Lee DH. The diagnostic validity of the (13)c-urea breath test in the gastrectomized patients: single tertiary center retrospective cohort study. J Cancer Prev. 2014;19:309-317. [PMID: 25574466 DOI: 10.15430/jcp.2014.19.4.309] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
54 Hori K, Miwa H, Matsumoto T. Efficacy of 2-week, second-line Helicobacter pylori eradication therapy using rabeprazole, amoxicillin, and metronidazole for the Japanese population. Helicobacter. 2011;16:234-240. [PMID: 21585610 DOI: 10.1111/j.1523-5378.2011.00842.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
55 Georgopoulos SD, Papastergiou V, Karatapanis S. Helicobacter pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy. Gastroenterol Res Pract. 2012;2012:757926. [PMID: 22778723 DOI: 10.1155/2012/757926.Epub2012Jun19] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
56 Liang J, Li J, Han Y, Xia J, Yang Y, Li W, Zhang S, Wu Y, Yuan Y, Li Z, Du Y, Chen M, Chen B, Jiang B, Bai Y, Wen Q, Wu K, Fan D. Helicobacter pylori Eradication with Ecabet Sodium, Omeprazole, Amoxicillin, and Clarithromycin Versus Bismuth, Omeprazole, Amoxicillin, and Clarithromycin Quadruple Therapy: A Randomized, Open-Label, Phase IV Trial. Helicobacter 2012;17:458-65. [DOI: 10.1111/j.1523-5378.2012.00971.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
57 Kim SY, Jung SW. [Helicobacter pylori eradication therapy in Korea]. Korean J Gastroenterol 2011;58:67-73. [PMID: 21873820 DOI: 10.4166/kjg.2011.58.2.67] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
58 Georgopoulos SD, Papastergiou V, Karatapanis S. Helicobacter  pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy. Gastroenterol Res Pract 2012;2012:757926. [PMID: 22778723 DOI: 10.1155/2012/757926] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
59 Park SH, Kangwan N, Park JM, Kim EH, Hahm KB. Non-microbial approach for Helicobacter pylori as faster track to prevent gastric cancer than simple eradication. World J Gastroenterol 2013; 19(47): 8986-8995 [PMID: 24379623 DOI: 10.3748/wjg.v19.i47.8986] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
60 Urgesi R, Cianci R, Riccioni ME. Update on triple therapy for eradication of Helicobacter pylori: current status of the art. Clin Exp Gastroenterol. 2012;5:151-157. [PMID: 23028235 DOI: 10.2147/ceg.s25416] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
61 Gou QY, Shi RH, Yu RB. Levofloxacin containing triple therapy vs standard triple therapy for eradication of Helicobacter pylori: A Meta-analysis. Shijie Huaren Xiaohua Zazhi 2014; 22(33): 5207-5211 [DOI: 10.11569/wcjd.v22.i33.5207] [Reference Citation Analysis]
62 dos Santos AA, Carvalho AA. Pharmacological therapy used in the elimination of Helicobacter pylori infection: A review. World J Gastroenterol 2015; 21(1): 139-154 [PMID: 25574087 DOI: 10.3748/wjg.v21.i1.139] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
63 Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66:6-30. [PMID: 27707777 DOI: 10.1136/gutjnl-2016-312288] [Cited by in Crossref: 1166] [Cited by in F6Publishing: 992] [Article Influence: 194.3] [Reference Citation Analysis]
64 Kim MS, Kim N, Kim SE, Jo HJ, Shin CM, Park YS, Lee DH. Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy. BMC Gastroenterol. 2013;13:138. [PMID: 24050512 DOI: 10.1186/1471-230x-13-138] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
65 Lee SY. [New guidelines for Helicobacter pylori treatment: comparisons between Korea and Japan]. Korean J Gastroenterol 2014;63:151-7. [PMID: 24651588 DOI: 10.4166/kjg.2014.63.3.151] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
66 Hwang JJ, Lee DH, Kang KK, Lee AR, Yoon H, Shin CM, Park YS, Kim N. Eradication rate and histological changes after Helicobacter pylori eradication treatment in gastric cancer patients following subtotal gastrectomy. World J Gastroenterol 2015; 21(13): 3936-3943 [PMID: 25852279 DOI: 10.3748/wjg.v21.i13.3936] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
67 O’Connor A, Gisbert JP, McNamara D, O’Morain C. Treatment of Helicobacter pylori infection 2011. Helicobacter. 2011;16 Suppl 1:53-58. [PMID: 21896086 DOI: 10.1111/j.1523-5378.2011.00881.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
68 Jheng GH, Wu IC, Shih HY, Wu MC, Kuo FC, Hu HM, Liu CJ, Hsu WH, Hu CT, Bair MJ, Kuo CH, Wu DC, Hsu PI. Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection. Biomed Res Int 2015;2015:163960. [PMID: 26090383 DOI: 10.1155/2015/163960] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
69 Ong S, Kim SE, Kim JH, Yi NH, Kim TY, Jung K, Park MI, Jung HY. Helicobacter pylori eradication rates with concomitant and tailored therapy based on 23S rRNA point mutation: A multicenter randomized controlled trial. Helicobacter. 2019;24:e12654. [PMID: 31411793 DOI: 10.1111/hel.12654] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
70 Hsieh MT, Chang WL, Wu CT, Yang HB, Kuo HY, Lin MY, Cheng HC, Tsai YC, Sheu BS. Optimizing the MIC breakpoints of amoxicillin and tetracycline for antibiotic selection in the rescue therapy of H. pylori with bismuth quadruple regimen. Eur J Clin Pharmacol 2020;76:1581-9. [PMID: 32591943 DOI: 10.1007/s00228-020-02938-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
71 Georgopoulos SD, Papastergiou V, Karatapanis S. Current options for the treatment of Helicobacter pylori. Expert Opin Pharmacother. 2013;14:211-223. [PMID: 23331077 DOI: 10.1517/14656566.2013.763926] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
72 Tae CH, Shim K. Current Strategies for Eradication of Helicobacter pylori in Korea. Korean J Helicobacter Up Gastrointest Res 2015;15:222. [DOI: 10.7704/kjhugr.2015.15.4.222] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
73 Hwang JJ, Lee DH, Lee AR, Yoon H, Shin CM, Park YS, Kim N. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication. World J Gastroenterol 2015; 21(26): 8132-8139 [PMID: 26185386 DOI: 10.3748/wjg.v21.i26.8132] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
74 Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112:212-239. [PMID: 28071659 DOI: 10.1038/ajg.2016.563] [Cited by in Crossref: 515] [Cited by in F6Publishing: 415] [Article Influence: 103.0] [Reference Citation Analysis]
75 Graham DY, Lee SY. How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly. Gastroenterol Clin North Am. 2015;44:537-563. [PMID: 26314667 DOI: 10.1016/j.gtc.2015.05.003] [Cited by in Crossref: 68] [Cited by in F6Publishing: 68] [Article Influence: 9.7] [Reference Citation Analysis]
76 Lv ZF, Wang FC, Zheng HL, Wang B, Xie Y, Zhou XJ, Lv NH. Meta-analysis: Is combination of tetracycline and amoxicillin suitable for Helicobacter pylori infection? World J Gastroenterol 2015; 21(8): 2522-2533 [PMID: 25741163 DOI: 10.3748/wjg.v21.i8.2522] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
77 Muñoz N, Sánchez-Delgado J, Baylina M, Puig I, López-Góngora S, Suarez D, Calvet X. Systematic review, meta-analysis, and meta-regression: Successful second-line treatment for Helicobacter pylori. Helicobacter 2018;23:e12488. [PMID: 29663581 DOI: 10.1111/hel.12488] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
78 Senatore FJ, Wilmot J, Birk JW. Helicobacter pylori treatment: Still a work in progress. Postgrad Med. 2016;128:152-157. [PMID: 26490697 DOI: 10.1080/00325481.2016.1103194] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
79 Chuah SK, Tsay FW, Hsu PI, Wu DC. A new look at anti-Helicobacter pylori therapy. World J Gastroenterol 2011; 17(35): 3971-3975 [PMID: 22046084 DOI: 10.3748/wjg.v17.i35.3971] [Cited by in CrossRef: 97] [Cited by in F6Publishing: 99] [Article Influence: 8.8] [Reference Citation Analysis]
80 Heo J, Jeon SW. Optimal treatment strategy for Helicobacter pylori: Era of antibiotic resistance. World J Gastroenterol 2014; 20(19): 5654-5659 [PMID: 24914324 DOI: 10.3748/wjg.v20.i19.5654] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
81 Lee ST, Lee DH, Lim JH, Kim N, Park YS, Shin CM, Jo HJ, Song IS. Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection. Gut Liver. 2015;9:478-485. [PMID: 25071068 DOI: 10.5009/gnl14020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]